Evaluate the incidence SARS CoV-2/COVID-19 infection associated with acute respiratory symptoms between VPM1002 vaccinated participants compared with placebo as determined through the detection of COVID-19 infection in participants using validated laboratory methods within approved testing facilities. The types of test methods will be determined based on testing procedures in place[Participants will provide data relating to acute respiratory symptoms monthly for up to 6 months (180 days) post-vaccine administration];Evaluate the incidence of laboratory confirmed SARS CoV-2/COVID-19 infection with severe; critical or life-threatening disease severity based on medical records for VPM1002 vaccinated participants compared with participants who receive placebo[Outcomes assessed for each occurrence for up to 6 months (180 days) post-vaccine administration]

Evaluate the incidence SARS CoV-2/COVID-19 infection associated with acute respiratory symptoms between VPM1002 vaccinated participants compared with placebo as determined through the detection of COVID-19 infection in participants using validated laboratory methods within approved testing facilities. The types of test methods will be determined based on testing procedures in place[Participants will provide data relating to acute respiratory symptoms monthly for up to 6 months (180 days) post-vaccine administration];Evaluate the incidence of laboratory confirmed SARS CoV-2/COVID-19 infection with severe; critical or life-threatening disease severity based on medical records for VPM1002 vaccinated participants compared with participants who receive placebo[Outcomes assessed for each occurrence for up to 6 months (180 days) post-vaccine administration]